All Stories

  1. Editorial overview: Tumour immunology: What's beyond today's success in tumor immunology

    Article • Current Opinion in Immunology, April 2016, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  2. Vaccines for established cancer: overcoming the challenges posed by immune evasion

    Article • Nature Reviews Drug Discovery, March 2016, Nature

    Prof. Dr. Sjoerd H van der Burg

  3. A beneficial tumor microenvironment in oropharyngeal squamous cell carcinoma is characterized by a high T cell and low IL-17+ cell frequency

    Article • Cancer Immunology Immunotherapy, February 2016, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  4. TAP-independent self-peptides enhance T cell recognition of immune-escaped tumors

    Article • Journal of Clinical Investigation, January 2016, American Society for Clinical Investigation

    Prof. Dr. Sjoerd H van der Burg

  5. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study

    Article • Cancer Immunology Immunotherapy, January 2016, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  6. Human papillomavirus 16-specific cell-mediated immunity in children born to mothers with incident cervical intraepithelial neoplasia (CIN) and to those constantly HPV negative

    Article • Journal of Translational Medicine, November 2015, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  7. The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome

    Article • Journal of Translational Medicine, September 2015, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  8. Abstract 2494: Vaccine-induced TNF alpha producing T cells synergize with cisplatin in tumor eradication

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Prof. Dr. Sjoerd H van der Burg

  9. New approaches in vaccine-based immunotherapy for human papillomavirus-induced cancer

    Article • Current Opinion in Immunology, August 2015, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  10. Therapeutic cancer vaccines

    Article • Journal of Clinical Investigation, July 2015, American Society for Clinical Investigation

    Prof. Dr. Sjoerd H van der Burg

  11. Synergy between chemotherapy and cancer vaccination

    Article • Aging, May 2015, Impact Journals, LLC

    Prof. Dr. Sjoerd H van der Burg

  12. Local and systemic XAGE-1b-specific immunity in patients with lung adenocarcinoma

    Article • Cancer Immunology Immunotherapy, May 2015, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  13. Cell mediated immunity against HPV16 E2, E6 and E7 peptides in women with incident CIN and in constantly HPV-negative women followed-up for 10-years

    Article • Journal of Translational Medicine, May 2015, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  14. Cooperative induction of apoptosis in NRAS mutant melanoma by inhibition of MEK and ROCK

    Article • Pigment Cell & Melanoma Research, April 2015, Wiley

    Prof. Dr. Sjoerd H van der Burg

  15. The interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation

    Article • Nature Communications, March 2015, Nature

    Prof. Dr. Sjoerd H van der Burg

  16. Data analysis as a source of variability of the HLA-peptide multimer assay: from manual gating to automated recognition of cell clusters

    Article • Cancer Immunology Immunotherapy, February 2015, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  17. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses

    Article • Biomaterials, February 2015, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  18. High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma

    Article • Nature Reports Stem Cells, December 2014, Nature

    Prof. Dr. Sjoerd H van der Burg

  19. CD40-Mediated Amplification of Local Immunity by Epithelial Cells Is Impaired by HPV

    Article • Journal of Investigative Dermatology, December 2014, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  20. Dominant contribution of the proteasome and metalloproteinases to TAP-independent MHC-I peptide repertoire

    Article • Molecular Immunology, November 2014, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  21. Cryopreservation of MHC multimers: Recommendations for quality assurance in detection of antigen specific T cells

    Article • Cytometry Part A, October 2014, Wiley

    Prof. Dr. Sjoerd H van der Burg

  22. Abstract 2938: Synergistic effects of properly timed HPV16 synthetic long peptide vaccination during standard carboplatin-paclitaxel chemotherapy in animals and in patients with metastatic cervical carcinoma

    Article • Cancer Research, September 2014, American Association for Cancer Research (AACR)

    Prof. Dr. Sjoerd H van der Burg

  23. Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival

    Article • International Journal of Cancer, September 2014, Wiley

    Prof. Dr. Sjoerd H van der Burg

  24. Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia

    Article • International Journal of Cancer, September 2014, Wiley

    Prof. Dr. Sjoerd H van der Burg

  25. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future

    Article • August 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  26. Harmonisation of short-term in vitro culture for the expansion of antigen-specific CD8+ T cells with detection by ELISPOT and HLA-multimer staining

    Article • Cancer Immunology Immunotherapy, August 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  27. Inhibition of CSF-1R Supports T-Cell Mediated Melanoma Therapy

    Article • PLoS ONE, August 2014, PLOS

    Prof. Dr. Sjoerd H van der Burg

  28. Near-genomewide RNAi screening for regulators of BRAFV600E-induced senescence identifiesRASEF, a gene epigenetically silenced in melanoma

    Article • Pigment Cell & Melanoma Research, May 2014, Wiley

    Prof. Dr. Sjoerd H van der Burg

  29. Effect of Hypoxic Stress on Migration and Characteristics of Monocytes in Uveal Melanoma

    Article • JAMA Ophthalmology, May 2014, American Medical Association (AMA)

    Prof. Dr. Sjoerd H van der Burg

  30. Immunoguiding, the Final Frontier in the Immunotherapy of Cancer

    Article • January 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  31. Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics

    Article • Journal for ImmunoTherapy of Cancer, January 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  32. Detection and functional assessment of regulatory T cells in clinical samples

    Article • Journal for ImmunoTherapy of Cancer, January 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  33. Human papillomavirus 16 E2-, E6- and E7-specific T-cell responses in children and their mothers who developed incident cervical intraepithelial neoplasia during a 14-year follow-up of the Finnish Family HPV cohort

    Article • Journal of Translational Medicine, January 2014, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  34. Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer

    Article • Expert Review of Vaccines, November 2013, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  35. Hierarchical Modeling for Rare Event Detection and Cell Subset Alignment across Flow Cytometry Samples

    Article • PLoS Computational Biology, July 2013, PLOS

    Prof. Dr. Sjoerd H van der Burg

  36. Human Papillomavirus (HPV) Upregulates the Cellular Deubiquitinase UCHL1 to Suppress the Keratinocyte's Innate Immune Response

    Article • PLoS Pathogens, May 2013, PLOS

    Prof. Dr. Sjoerd H van der Burg

  37. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence

    Article • Nature, May 2013, Nature

    Prof. Dr. Sjoerd H van der Burg

  38. Efficient ex vivo induction of T cells with potent anti-tumor activity by protein antigen encapsulated in nanoparticles

    Article • Cancer Immunology Immunotherapy, April 2013, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  39. Genome-wide promoter methylation analysis identifies epigenetic silencing ofMAPK13in primary cutaneous melanoma

    Article • Pigment Cell & Melanoma Research, April 2013, Wiley

    Prof. Dr. Sjoerd H van der Burg

  40. Abstract 1254: Tumor infiltrating M1 macrophages work side by side with T cells to prolong the survival in patients with cervical carcinoma.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Prof. Dr. Sjoerd H van der Burg

  41. Abstract 4712: Chemotherapy-enhanced NFkB pathway activation in gynecological cancers increases the differentiation of monocytes to M2 macrophages instead of dendritic cells.

    Article • Cancer Research, April 2013, American Association for Cancer Research (AACR)

    Prof. Dr. Sjoerd H van der Burg

  42. Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer

    Article • Seminars in Immunology, April 2013, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  43. Comprehensive Immunomonitoring to Guide the Development of Immunotherapeutic Products for Cancer

    Article • January 2013, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  44. Alternative peptide repertoire of HLA-E reveals a binding motif that is strikingly similar to HLA-A2

    Article • Molecular Immunology, January 2013, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  45. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial

    Article • Journal of Translational Medicine, January 2013, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  46. Immunotherapy of Human Papilloma Virus Induced Disease

    Article • The Open Virology Journal, December 2012, Bentham Science Publishers

    Prof. Dr. Sjoerd H van der Burg

  47. Serum-free freezing media support high cell quality and excellent ELISPOT assay performance across a wide variety of different assay protocols

    Article • Cancer Immunology Immunotherapy, November 2012, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  48. Therapy of Human Papillomavirus-Related Disease

    Article • Vaccine, November 2012, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  49. The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study

    Article • Cancer Immunology Immunotherapy, September 2012, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  50. Different Subsets of Tumor-Infiltrating Lymphocytes Correlate with Macrophage Influx and Monosomy 3 in Uveal Melanoma

    Article • Investigative Ophthalmology & Visual Science, August 2012, Association for Research in Vision and Ophthalmology (ARVO)

    Prof. Dr. Sjoerd H van der Burg

  51. Interleukin-6/interleukin-6 Receptor Pathway as a New Therapy Target in Epithelial Ovarian Cancer

    Article • Current Pharmaceutical Design, August 2012, Bentham Science Publishers

    Prof. Dr. Sjoerd H van der Burg

  52. Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy

    Article • Expert Review of Vaccines, July 2012, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  53. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

    Article • Cancer Immunology Immunotherapy, June 2012, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  54. Harmonization of the intracellular cytokine staining assay

    Article • Cancer Immunology Immunotherapy, May 2012, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  55. Identification of a novel antigen processing pathway

    Article • Molecular Immunology, May 2012, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  56. Mechanism of superior cross-presentation of synthetic long peptides in comparison with protein for therapeutic cancer vaccination

    Article • Molecular Immunology, May 2012, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  57. The simultaneous ex vivo detection of low-frequency antigen-specific CD4+ and CD8+ T-cell responses using overlapping peptide pools

    Article • Cancer Immunology Immunotherapy, April 2012, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  58. Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study

    Article • International Journal of Cancer, January 2012, Wiley

    Prof. Dr. Sjoerd H van der Burg

  59. Mechanisms of Peptide Vaccination in Mouse Models

    Article • January 2012, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  60. Peptide transporter TAP mediates between competing antigen sources generating distinct surface MHC class I peptide repertoires

    Article • European Journal of Immunology, October 2011, Wiley

    Prof. Dr. Sjoerd H van der Burg

  61. T-cell immune monitoring assays to guide the development of new cancer vaccines

    Article • August 2011, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  62. T-cell immune monitoring assays to guide the development of new cancer vaccines

    Article • July 2011, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  63. Colorectal cancer vaccines in clinical trials

    Article • Expert Review of Vaccines, June 2011, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  64. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer

    Article • International Journal of Cancer, May 2011, Wiley

    Prof. Dr. Sjoerd H van der Burg

  65. Therapeutic vaccination against human papilloma virus induced malignancies

    Article • Current Opinion in Immunology, April 2011, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  66. Successful treatment of metastatic melanoma by adoptive transfer of blood-derived polyclonal tumor-specific CD4+ and CD8+ T cells in combination with low-dose interferon-alpha

    Article • Cancer Immunology Immunotherapy, March 2011, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  67. Human Papillomavirus Deregulates the Response of a Cellular Network Comprising of Chemotactic and Proinflammatory Genes

    Article • PLoS ONE, March 2011, PLOS

    Prof. Dr. Sjoerd H van der Burg

  68. Immunotherapy for persistent viral infections and associated disease

    Article • Trends in Immunology, March 2011, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  69. Identification and manipulation of tumor associated macrophages in human cancers

    Article • Journal of Translational Medicine, January 2011, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  70. Tumor-infiltrating Cytotoxic T Lymphocytes as Independent Prognostic Factor in Epithelial Ovarian Cancer With Wilms Tumor Protein 1 Overexpression

    Article • Journal of Immunotherapy, January 2011, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  71. Generating HPV specific T helper cells for the treatment of HPV induced malignancies using TCR gene transfer

    Article • Journal of Translational Medicine, January 2011, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  72. Influenza matrix 1-specific human CD4+FOXP3+ and FOXP3− regulatory T cells can be detected long after viral clearance

    Article • European Journal of Immunology, September 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg

  73. The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors

    Article • International Journal of Cancer, April 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg

  74. The nonpolymorphic MHC Qa-1 b mediates CD8 + T cell surveillance of antigen-processing defects

    Article • The Journal of Experimental Medicine, March 2010, Rockefeller University Press

    Prof. Dr. Sjoerd H van der Burg

  75. Anti-inflammatory M2 type macrophages characterize metastasized and tyrosine kinase inhibitor-treated gastrointestinal stromal tumors

    Article • International Journal of Cancer, January 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg, Professor Pancras C.W. Hogendoorn

  76. A prospective study on the natural course of low-grade squamous intraepithelial lesions and the presence of HPV16 E2-, E6- and E7-specific T-cell responses

    Article • International Journal of Cancer, January 2010, Wiley

    Prof. Dr. Sjoerd H van der Burg

  77. The nonpolymorphic MHC Qa-1 b mediates CD8 + T cell surveillance of antigen-processing defects

    Article • The Journal of Experimental Medicine, December 2009, Rockefeller University Press

    Prof. Dr. Sjoerd H van der Burg

  78. 2-Azidoalkoxy-7-hydro-8-oxoadenine derivatives as TLR7 agonists inducing dendritic cell maturation

    Article • Bioorganic & Medicinal Chemistry Letters, April 2009, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  79. Chirality of TLR-2 ligand Pam3CysSK4 in fully synthetic peptide conjugates critically influences the induction of specific CD8+ T-cells

    Article • Molecular Immunology, March 2009, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  80. Human immunodeficiency virus and human papilloma virus - why HPV-induced lesions do not spontaneously resolve and why therapeutic vaccination can be successful

    Article • Journal of Translational Medicine, January 2009, Springer Science + Business Media

    Prof. Dr. Sjoerd H van der Burg

  81. T-regulatory cells in tumour-specific vaccination strategies

    Article • Expert Opinion on Biological Therapy, August 2008, Informa Healthcare

    Prof. Dr. Sjoerd H van der Burg

  82. Immune Response Against Frameshift-Induced Neopeptides in HNPCC Patients and Healthy HNPCC Mutation Carriers

    Article • Gastroenterology, August 2008, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  83. Prediction of the immunogenic potential of frameshift-mutated antigens in microsatellite instable cancer

    Article • International Journal of Cancer, May 2008, Wiley

    Prof. Dr. Sjoerd H van der Burg

  84. Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

    Article • Nature Reviews Drug Discovery, May 2008, Nature

    Prof. Dr. Sjoerd H van der Burg

  85. Tumor-specific regulatory T cells in cancer patients

    Article • Human Immunology, April 2008, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  86. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

    Article • European Journal of Immunology, April 2008, Wiley

    Prof. Dr. Sjoerd H van der Burg

  87. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding

    Article • Expert Review of Vaccines, February 2008, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  88. Chapter 13 Therapeutic HPV vaccines

    Article • January 2008, Oxford University Press (OUP)

    Prof. Dr. Sjoerd H van der Burg

  89. Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia

    Article • International Journal of Cancer, January 2008, Wiley

    Prof. Dr. Sjoerd H van der Burg

  90. Corrigendum to “Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists” [Vaccine 2007;25(8):1379–89]

    Article • Vaccine, October 2007, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  91. Design and development of synthetic peptide vaccines: past, present and future

    Article • Expert Review of Vaccines, August 2007, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  92. Spontaneous tumor rejection by cbl-b –deficient CD8 + T cells

    Article • The Journal of Experimental Medicine, April 2007, Rockefeller University Press

    Prof. Dr. Sjoerd H van der Burg

  93. Multiple CD4 and CD8 T-cell activation parameters predict vaccine efficacy in vivo mediated by individual DC-activating agonists

    Article • Vaccine, February 2007, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  94. Genetic variation of antigen processing machinery components and association with cervical carcinoma

    Article • Genes Chromosomes and Cancer, January 2007, Wiley

    Prof. Dr. Sjoerd H van der Burg

  95. P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy

    Article • International Journal of Cancer, January 2007, Wiley

    Prof. Dr. Sjoerd H van der Burg

  96. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts

    Article • International Journal of Cancer, January 2007, Wiley

    Prof. Dr. Sjoerd H van der Burg

  97. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and –DP as a restriction element

    Article • International Journal of Cancer, January 2007, Wiley

    Prof. Dr. Sjoerd H van der Burg

  98. Chemical synthesis of the HPV16 E7 protein

    Article • Tetrahedron Letters, December 2006, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  99. Improved peptide vaccine strategies, creating synthetic artificial infections to maximize immune efficacy

    Article • Advanced Drug Delivery Reviews, October 2006, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  100. Synthesis of 2-alkoxy-8-hydroxyadenylpeptides: Towards synthetic epitope-based vaccines

    Article • Bioorganic & Medicinal Chemistry Letters, June 2006, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  101. p53: A Potential Target Antigen for Immunotherapy of Cancer

    Article • Annals of the New York Academy of Sciences, January 2006, Wiley

    Prof. Dr. Sjoerd H van der Burg

  102. Vaccination for Treatment and Prevention of Cancer in Animal Models

    Article • January 2006, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  103. Exploration of the Course of the p53 Specific Immune Response During Primary Treatment for Ovarian Cancer

    Article • Journal of Immunotherapy, November 2005, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  104. Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease

    Article • International Journal of Cancer, September 2005, Wiley

    Prof. Dr. Sjoerd H van der Burg

  105. Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia

    Article • International Journal of Cancer, August 2005, Wiley

    Prof. Dr. Sjoerd H van der Burg

  106. p53-Specific serum antibodies are not associated with a history of skin carcinoma in renal transplant recipients and immunocompetent individuals

    Article • Journal of Dermatological Science, June 2005, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  107. Immunology: Innate and Adaptive Immune Responses

    Article • Papillomavirus Report, January 2005, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  108. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model

    Article • Vaccine, December 2004, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  109. Rapid enrichment of human papillomavirus (HPV)‐specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer

    Article • International Journal of Cancer, November 2004, Wiley

    Prof. Dr. Sjoerd H van der Burg

  110. Competition‐Based Cellular Peptide Binding Assay forHLAClass I

    Article • Current Protocols in Immunology, June 2004, Wiley

    Prof. Dr. Sjoerd H van der Burg

  111. Immunology: prophylactic vaccination

    Article • Papillomavirus Report, May 2004, Taylor & Francis

    Prof. Dr. Sjoerd H van der Burg

  112. Magnitude and polarization of P53-specific T-helper immunity in connection to leukocyte infiltration of colorectal tumors

    Article • International Journal of Cancer, September 2003, Wiley

    Prof. Dr. Sjoerd H van der Burg

  113. Safety of intravenous administration of a canarypox virus encoding the human wild-type p53 gene in colorectal cancer patients

    Article • Cancer Gene Therapy, July 2003, Nature

    Prof. Dr. Sjoerd H van der Burg

  114. Competition-based cellular peptide binding assays for 13 prevalent HLA class I alleles using fluorescein-labeled synthetic peptides

    Article • Human Immunology, February 2003, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  115. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development

    Article • Virus Research, November 2002, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  116. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes

    Article • Immunological Reviews, October 2002, Wiley

    Prof. Dr. Sjoerd H van der Burg

  117. Natural T cell response against HPV16 and development of optimal peptide based vaccine

    Article • European Journal of Cancer, April 2001, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  118. Identification of three non‐VNTR MUC1‐derived HLA‐A*0201‐restricted T‐cell epitopes that induce protective anti‐tumor immunity in HLA‐A2/Kb‐transgenic mice

    Article • International Journal of Cancer, February 2001, Wiley

    Prof. Dr. Sjoerd H van der Burg

  119. Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer

    Article • European Journal of Immunology, January 2001, Wiley

    Prof. Dr. Sjoerd H van der Burg

  120. Design and evaluation of antigen-specific vaccination strategies against cancer

    Article • Current Opinion in Immunology, October 2000, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  121. Strategies for immunotherapy of cancer

    Article • January 2000, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  122. Molecular Mimicry of Human Cytochrome P450 by Hepatitis C Virus at the Level of Cytotoxic T Cell Recognition

    Article • The Journal of Experimental Medicine, July 1999, Rockefeller University Press

    Prof. Dr. Sjoerd H van der Burg

  123. Cytotoxic T lymphocytes in HIV-1 infection: a killing paradox?

    Article • Immunology Today, July 1998, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  124. Affinity, specificity and T-cell-receptor diversity of melanoma-specific CTL generatedin vitro against a single tyrosinase epitope

    Article • International Journal of Cancer, September 1997, Wiley

    Prof. Dr. Sjoerd H van der Burg

  125. Identification of Potential HLA-A *0201 Restricted CTL Epitopes Derived from the Epithelial Cell Adhesion Molecule (Ep-CAM) and the Carcinoembryonic Antigen (CEA)

    Article • Human Immunology, March 1997, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  126. Do epitopes derived form autoantigens display low affinity for MHC class I?

    Article • Immunology Today, February 1997, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  127. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope

    Article • International Journal of Cancer, January 1997, Wiley

    Prof. Dr. Sjoerd H van der Burg

  128. Peptide-pulsed dendritic cells induce tumoricidal cytotoxic T lymphocytes from healthy donors against stably HLA-A*0201-binding peptides from the Melan-A/MART-1 self antigen

    Article • European Journal of Immunology, August 1996, Wiley

    Prof. Dr. Sjoerd H van der Burg

  129. Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors

    Article • European Journal of Immunology, September 1995, Wiley

    Prof. Dr. Sjoerd H van der Burg

  130. The Use of Epstein-Barr Virus-Transformed B Lymphocyte Cell Lines in a Peptide-Reconstitution Assay

    Article • Journal of Immunotherapy, August 1995, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  131. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase

    Article • AIDS, February 1995, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  132. Induction of a primary human cytotoxic T-lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase

    Article • AIDS, January 1995, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  133. p53, a potential target for tumor-directed T cells

    Article • Immunology Letters, May 1994, Elsevier

    Prof. Dr. Sjoerd H van der Burg

  134. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild-type p53

    Article • European Journal of Immunology, September 1993, Wiley

    Prof. Dr. Sjoerd H van der Burg

  135. Characterization of Cytotoxic T Lymphocyte Epitopes of a Self-Protein, p53, and a Non-Self-Protein, Influenza Matrix

    Article • Journal of Immunotherapy, August 1993, Wolters Kluwer Health

    Prof. Dr. Sjoerd H van der Burg

  136. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes

    Article • European Journal of Immunology, June 1993, Wiley

    Prof. Dr. Sjoerd H van der Burg

  137. Faculty of 1000 evaluation for Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival.

    Article • Faculty of 1000, Ltd.

    Prof. Dr. Sjoerd H van der Burg

  138. Faculty of 1000 evaluation for Synergistic inhibition of natural killer cells by the nonsignaling molecule CD94.

    Article • Faculty of 1000, Ltd.

    Prof. Dr. Sjoerd H van der Burg

  139. Faculty of 1000 evaluation for Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity.

    Article • Faculty of 1000, Ltd.

    Prof. Dr. Sjoerd H van der Burg

  140. Faculty of 1000 evaluation for Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.

    Article • Faculty of 1000, Ltd.

    Prof. Dr. Sjoerd H van der Burg